Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.4802
-0.0198 (-3.96%)
At close: Jul 15, 2025, 4:00 PM
0.4771
-0.0031 (-0.65%)
Pre-market: Jul 16, 2025, 5:05 AM EDT
Sangamo Therapeutics Employees
Sangamo Therapeutics had 183 employees as of December 31, 2024. The number of employees decreased by 222 or -54.81% compared to the previous year.
Employees
183
Change (1Y)
-222
Growth (1Y)
-54.81%
Revenue / Employee
$348,393
Profits / Employee
-$434,148
Market Cap
114.10M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SGMO News
- 21 days ago - Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business Wire
- 2 months ago - Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results - Business Wire
- 2 months ago - Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - Business Wire
- 2 months ago - Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day - Business Wire
- 2 months ago - Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Business Wire
- 2 months ago - Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease - Business Wire
- 2 months ago - Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - Business Wire